Distalmotion Secures $150M Series G to Expand DEXTER Surgical Robot in U.S. Ambulatory Surgery Centers
核心洞察
Swiss medtech company Distalmotion (搜索) raised $150 million in Series G financing led by Revival Healthcare Capital (搜索) to accelerate U.S. commercial expansion of its DEXTER (搜索) surgical robot.
DEXTER (搜索) has received three FDA authorizations for gallbladder, hysterectomy, and hernia repair procedures, with the compact mobile system designed to integrate into existing operating rooms without structural modifications.
The company is targeting the fast-growing ambulatory surgery center market, where DEXTER (搜索)'s streamlined design offers advantages over larger robotic platforms that require dedicated infrastructure.
Swiss medtech company Distalmotion (搜索) has completed a $150 million Series G financing round to accelerate the U.S. commercial expansion of its DEXTER (搜索) surgical robot, positioning the company to compete in the rapidly growing ambulatory surgery center market. The funding round was led by Revival Healthcare Capital (搜索) with participation from existing investors.
FDA Clearances Enable U.S. Market Entry
DEXTER (搜索) has secured three FDA authorizations for use in gallbladder, hysterectomy, and hernia repair procedures, clearing regulatory pathways for broader U.S. adoption. The platform has already demonstrated clinical utility, treating nearly 3,000 patients across Europe and the United States since its introduction.
The surgical robot is designed as a compact, mobile system that integrates into existing operating rooms without requiring structural modifications. This approach contrasts with traditional robotic platforms that demand dedicated infrastructure and substantial institutional resources for implementation.
Targeting Ambulatory Surgery Centers
Distalmotion (搜索) is focusing its U.S. expansion on ambulatory surgery centers, which represent one of the fastest-growing segments in surgical care due to increasing demand for efficient outpatient procedures. The company's strategy addresses specific barriers that have limited robotic surgery adoption in these settings.
According to a September paper published in the Journal of Robotic Surgery, physicians identified that existing robotic platforms requiring dedicated operating room space, institutional resources for surgeon training, and substantial infrastructure create barriers to robot use in ASCs. These requirements have limited uptake at sites that could benefit from minimally invasive platforms.
Platform Design and Clinical Features
DEXTER (搜索)'s open architecture allows surgeons to use their preferred visualization systems and laparoscopic electrosurgical generators. The platform enables surgeons to alternate seamlessly between laparoscopic and robotic modes, while its sterile open console maintains direct visibility of the patient and surgical team.
CEO Greg Roche described the funding as an important step in the company's expansion, stating that "ASCs represent a tremendous opportunity for Dexter (搜索)" as Distalmotion (搜索) enters the next phase of its U.S. commercialization plan. He emphasized that simplified robotic workflows remain central to the company's mission to broaden access to minimally invasive surgery.
Competitive Landscape
The expansion puts Distalmotion (搜索) in direct competition with Intuitive Surgical, the market leader in soft-tissue robotics. Intuitive executives recently discussed trends where hospitals purchasing the latest da Vinci 5 (搜索) systems redeploy older Xi robots in ASCs, indicating growing interest in the ambulatory surgery market.
Intuitive CFO Jamie Samath noted that the original capital cost of robots represents a bigger constraint on ASC installations than Medicare coverage and commercial rates. While the ASC installed base remains relatively small, procedure growth at these sites is "quite a bit accretive to what we see in terms of overall U.S. procedure growth," driving continued market interest.